(VIANEWS) – ESSILORLUXOTTICA (EL.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| ESSILORLUXOTTICA (EL.PA) | €172.86 | 1.92% | 6.44% |
| IPSEN (IPN.PA) | €110.50 | 1.08% | 12.52% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. ESSILORLUXOTTICA (EL.PA)
1.92% Forward Dividend Yield and 6.44% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €5.21.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 33.18. Meaning, the purchaser of the share is investing €33.18 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.44%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 22, 2023, the estimated forward annual dividend rate is 3.23 and the estimated forward annual dividend yield is 1.92%.
Volume
Today’s last reported volume for ESSILORLUXOTTICA is 45475 which is 88.14% below its average volume of 383729.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ESSILORLUXOTTICA’s stock is considered to be overbought (>=80).
More news about ESSILORLUXOTTICA.
2. IPSEN (IPN.PA)
1.08% Forward Dividend Yield and 12.52% Return On Equity
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Earnings Per Share
As for profitability, IPSEN has a trailing twelve months EPS of €4.89.
PE Ratio
IPSEN has a trailing twelve months price to earnings ratio of 22.6. Meaning, the purchaser of the share is investing €22.6 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.52%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 2, 2023, the estimated forward annual dividend rate is 1.2 and the estimated forward annual dividend yield is 1.08%.
Volatility
IPSEN’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.60%, a negative 0.46%, and a positive 1.22%.
IPSEN’s highest amplitude of average volatility was 1.03% (last week), 1.52% (last month), and 1.22% (last quarter).
Volume
Today’s last reported volume for IPSEN is 10648 which is 85.29% below its average volume of 72417.
Yearly Top and Bottom Value
IPSEN’s stock is valued at €110.50 at 11:30 EST, way below its 52-week high of €130.70 and way higher than its 52-week low of €94.85.
More news about IPSEN.
